(KMOX) — A British drug manufacturer is hoping for a big score from consumers and a green light from the FDA for its medical marijuana mouth spray in 2013.
Seven countries including the UK, Spain and Germany have approved Sativex to treat patients with multiple sclerosis. Makers GW Pharmaceuticals hopes the drug will be used as a prescribed replacement to medical marijuana in the United States.
Patients take the drug by spraying it into their mouths like a breath spray with a dosage meter. This way, GW Pharmaceuticals says people can derive maximum benefit from the drug without feeling a “high.”
GW’s website says side effects can include dizziness, which occurs mainly in the first few weeks of treatment, and fatigue. There is no mention of the munchies.
Sativex contains pure amounts of delta 9-THC and cannabidiol — marijuana’s two best-known active ingredients and is the world’s first pharmaceutical drug made from grown marijuana rather than its synthetic equivalent. The drug is grown under computer-monitored conditions in secret greenhouses located in southern Britain.
GW Pharmaceuticals was founded specifically to bring cannabinoid medications to market and is traded on the Alternative Investment Market (AIM) of the London Stock Exchange.
(TM and © Copyright 2011 CBS Radio Inc. and its relevant subsidiaries. CBS RADIO and EYE Logo TM and Copyright 2011 CBS Broadcasting Inc. Used under license. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. The Associated Press contributed to this report.)